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Stüve-Wiedemann syndrome (STWS; OMIM #610559) is a rare bent-bone dysplasia that includes radiologic bone
anomalies, respiratory distress, feeding difficulties, and hyperthermic episodes. STWS usually results in infant mortality,
yet some STWS patients survive into and, in some cases, beyond adolescence. STWS is caused by a mutation in the
leukemia inhibitory factor receptor (LIFR) gene, which is inherited in an autosomally recessive pattern. Most LIFR
mutations resulting in STWS are null mutations which cause instability of the mRNA and prevent the formation of
LIFR, impairing the signaling pathway. LIFR signaling usually follows the JAK/STAT3 pathway, and is initiated by several
interleukin-6-type cytokines. STWS is managed on a symptomatic basis since there is no treatment currently available.
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History
Stüve-Wiedemann syndrome (STWS) was first described
in 1971, presenting in two sisters with congenital bowing
of the tibia and femur, abnormally positioned feet, and
camptodactyly. Both patients experienced respiratory dis-
tress and consequently died within a few days of birth.
One of the patients also suffered from deglutination diffi-
culty and hyperthermia. Stüve and Wiedemann suspected
that the syndrome had autosomal recessive inheritance
since the patients were sisters [1,2]. Although the progno-
sis of STWS remains poor, recent reports show that some
STWS patients survive at least into early adolescence
[3,4], and beyond.Classification
Surviving STWS patients were found to be phenotypic-
ally identical to Schwartz-Jampel syndrome type 2 (SJS2)
survivors. Therefore, SJS2 and STWS are now considered
to be the same disorder, and the title “Schwartz-Jampel
Syndrome type 2” has been dropped [5,6]. Both SJS2 and
STWS have been linked to a mutation of the leukemia in-
hibitory factor receptor (LIFR) gene on chromosome
5p13.1 [7].* Correspondence: joxford@boisestate.edu
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unless otherwise stated.STWS includes autonomic nerve dysfunction [3], and
the related ciliary neurotrophic factor receptor (CNTFR)
gene has also been linked to autonomic nervous system
dysfunction [8]. Therefore, STWS is also included in the
family of CNTFR pathway-related disorders [9]. This clas-
sification exemplifies the clinical overlaps between STWS,
Crisponi syndrome, which includes facial weakness, feed-
ing difficulties, camptodactyly and hyperthermia in infancy
followed by scoliosis, and cold-induced sweating in adoles-
cence, and cold-induced sweating syndrome (CISS) [9,10].
However, the skeletal features of STWS allow it to also be
classified within the group of bent-bone dysplasias [11].
STWS is found across multiple ethnic groups in multiple
regions of the world including North America, Europe,
and the Middle East [7,12,13]. However, STWS appears to
be more common in the United Arab Emirates [14], as well
as in Oman and Yemen [12,15].Clinical manifestations
STWS is a rare autosomal recessive bent-bone dysplasia
(OMIM #601559). It is characterized by bowing of the
long bones with cortical thickening and rarefaction, wide
and blurred margins of the metaphyses, contracture and
limited mobility of elbows and knees, osteopenia, flared
iliac wings, hypoplasia of the lower ilia, and an abnormal
trabecular shape [1,7,13,16]. Additional features include
camptodactyly, contracture of fingers, and symptoms ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ten months of age, who was later diagnosed with STWS.
Most individuals suffering from STWS do not survive
beyond the first few months of life due to respiratory
distress, difficulties with feeding and swallowing, or
hyperthermic episodes [1,7,10,12,13,17-19]. Patients that
do survive show an improvement in prognosis as a nor-
mal breathing rhythm is established and the ability to
swallow is gained, yet difficulties with swallowing can
still occur later in childhood [13].
With age, there is progressive bowing of the long
bones with tubulation of diaphyses, rarefaction and stri-
ation of metaphyses, and destruction of the femoral
heads [12]. Severe spinal deformities arise, along with
streaky osteoporosis and spontaneous fractures. TheTable 1 Diagnostic characteristics of STWS
Organ system Neonatal Chil
Embryonic Oligohydramnios
Intrauterine growth restriction; low birth
weight, length and head circumference
Growth
Skeletal Micromelia, bowing of the long bones
with cortical thickening, wide






Osteopenia or osteoporosis Osteopenia o












Excessive sweating Excessive an
swe










Open cells in the table indicate no available treatment. Some features generally im
become progressively worse (i.e., bowing of the long bones).joints are prominent and show restricted mobility.
Temperature instability remains, and there is excessive,
and sometimes paradoxical sweating. Other signs of dys-
autonomia persist, such as a smooth tongue, absent cor-
neal and patellar reflexes, and reduced pain sensation.
Physical growth and motor development is delayed, but
intelligence is normal [7,12,13].
In some cases, it is possible to predict the presence of
STWS before birth via ultrasound. Prenatal symptoms
can sometimes be seen in the late second- or third tri-
mester. The prenatal symptoms of STWS include oligohy-
dramnios, intrauterine growth restriction despite normal
Doppler findings about the umbilical artery, camptodac-
tyly, bowing of the lower bones affecting the tibia more








liosis Corrective surgery [7,12,13]
r osteoporosis Bisphosphonates, calcium, vitamin
D, human growth hormone,




























l opacities Keratectomy [17,120]
[18]
prove over time (i.e., respiratory distress and dysphagia), while other features
Figure 1 Image of STWS patient at 10 months of age. Facial
features and contracture of fingers are evident. Patient carries two
mutations in the LIFR gene; 1) a duplication of 22 nucleotides within
exon 4, causing a frameshift predicted to result in a premature stop
codon following five unique amino acids, and 2) a deletion of nine
nucleotides within exon 12, resulting in the deletion of three amino
acids at the protein level. Both mutations occur within the region of
the gene encoding the extracellular domain. The mutation resulting in
the premature stop codon is anticipated to result in mRNA instability,
and it is therefore likely to result in a null mutation. These mutations
are unique, having not been previously described. Photograph printed
with permission from patient, now age 23.
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Genetic mutations responsible for STWS
Dagoneau et al. determined that the leukemia inhibitory
factor receptor (LIFR) gene on chromosome 5p13.1 is
responsible for STWS [7]. Their findings were reinforced
by the observation that LIFR-/- mice have reduced fetal
bone volume, an increased number of osteoclasts, reduced
numbers of astrocytes in the spinal cord and brain, and
perinatal death [21]. The mouse phenotype is considered
to be similar to that of STWS [7]. Furthermore, most pa-
tients with STWS have a mutation within the LIFR gene
[20]. Many STWS patients in the United Arab Emirates
have an identical frameshift mutation in the LIFR gene
that results in a premature stop codon [20].
The mutated LIFR gene is inherited in an autosomal
recessive pattern. The mutations reported have been ei-
ther missense or nonsense mutations, with the majority
being nonsense mutations within the exons encoding
the extracellular domain [7]. Fourteen distinct null mu-
tations were observed in 19 families, most of which re-
sulted in premature stop codons which altered the
stability of the mRNA, resulting in an absence of theLIFR protein and impairment of the LIFR signaling path-
way [7]. The LIFR gene has 19 exons and normally en-
codes a transmembrane protein which is 1,097 amino
acids long [7,22,23].
Genetic variability
Interestingly, not all patients who are diagnosed with
STWS have an identified LIFR mutation [13,19]. The
gene(s) responsible for the STWS phenotype in these
exceptional cases have not been identified. This variability
suggests that modifier genes may play a role in STWS,
as well [13]. Other genes within the candidate region
(chromosome 5p13.1 from locus D5S194 to D5S1457)
mapped by Dagoneau et al. included FLJ39155 (EGFLAM
or Pikachurin, a proteoglycan), disabled-2 (DAB2), comple-
ment 9 (C9), Fyn-binding protein (FYB), and oncostatin M
receptor (OSMR) [7]. While these genes may play a role as
disease modifiers or may be potential candidates for those
cases of STWS that are not linked to a mutation in LIFR,
to date, limited information exists to support the likelihood
of the involvement of these genes in skeletal, respiratory or
neurological symptoms associated with the syndrome. For
example, a neurologic function has been described for the
FLJ39155 locus. FLJ39155 gene product has been localized
to the synaptic cleft of the photoreceptor ribbon synapse
and gene disruption experiments demonstrated the neces-
sity of this protein for proper synaptic signal transmission
and visual function [24]. Knockout of this gene selectively
disrupts synaptogenesis between photoreceptor and bipolar
cells. Additionally, micro-duplications of the short arm of
chromosome 5 that include the 5p13.1 region have been
linked to neurologic symptoms [25]. This region includes
the genes FYB, C9, and DAB-2.
Respiratory function has been associated with DAB-2.
DAB-2 is a clathrin-associated sorting protein (CLASP)
that contributes to clathrin recruitment, vesicle formation,
and cargo selection. In the lungs, cystic fibrosis transmem-
brane conductance regulator, a cAMP-activated chloride
channel expressed in the apical plasma membrane of hu-
man airway epithelial cells, is endocytosed in a DAB-2-
dependent manner [26]. DAB-2 also plays a role in bone
morphogenetic protein signaling [27] and nerve cell differ-
entiation [28].
Complement C9 may play a role in skeletal develop-
ment through its function during endochondral ossifica-
tion [29], and in respiratory function [30], and has been
implicated in demyelination diseases [31]. FYB has been
linked to osteoclastogenesis [32] and lung physiology
[33]. Additionally, a neurologic function has been de-
scribed for FYB through an association with hereditary
motor-sensory neuropathy [34].
OSMR plays a key role in bone homeostasis as demon-
strated by the OSMR(-/-) mouse, which exhibits an
osteopetrotic phenotype due to an effect on osteoclast
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in the respiratory system [37], and the nervous system
[38], as well as metabolic symptoms such as mature-
onset obesity, severe hepatic steatosis, and insulin resist-
ance [39]. Other proteins that play an essential role in
the LIFR pathway as ligands or as competing receptor,
such as the cytokine receptor-like factor 1 (CRLF1),
cardiotrophin-like cytokine factor 1 (CLCF1), and ciliary
neurotrophic factor (CNTF) may play a role in STWS
[13] and are discussed in more detail below.
The LIFR protein and its signaling pathway
The LIFR protein
The LIFR protein (also called glycoprotein-190; gp 190)
is composed of a signal peptide followed by three main
domains. The extracellular domain (45-833aa) includes
two cytokine receptor homology domains (CRH1 and
CRH 2), one Ig-like domain (Ig), and one type III fibro-
nectin domain with three modules (FNIII). Following
the extracellular domain is the transmembrane domain
(TM; 834-858aa), and finally the cytoplasmic domain
(CD; 859-1097aa; Figure 2).
The LIFR signaling pathway
LIFR binds with low affinity to several IL-6 family
members, including leukemia inhibitory factor (LIF),
oncostatin-M (OSM), cardiotrophin-1 (CT-1, also abbre-
viated as CTF-1), ciliary neurotrophic factor (CNTF), and
cardiotrophin-like cytokine factor 1 (CLCF-1, also abbre-
viated as CLC) (Figure 3) [40-43]. Both LIF and OSM can
bind to the LIFR. LIF binds to LIFRβ, which then recruits
gp130 for higher affinity and cell signaling [23]. In con-
trast, OSM binds gp130 with low affinity but has little
to no biological activity unless a second receptor chain
is recruited, either the LIFRβ or the more highly spe-
cific OSMRβ [44-47]. CT-1 binds to gp130 and LIFR
[48], while CNTF first binds to ciliary neurotrophic fac-
tor receptor (CNTFRα) before recruiting LIFR. [49]
Cardiotrophin-like cytokine factor 1 (CLCF-1) forms a
heterodimer with either cytokine receptor-like factor 1
(CRLF1) or soluble ciliary neurotrophic factor receptor
(sCNTFR) and competes for this same receptor com-
plex (Figure 3; [13,50-52]).Figure 2 The LIFR protein with domains and exons shown. The numbers
(CRH1, Ig, CRH2, FNIII, TD and CD) are illustrated within their corresponding re
SP: signal peptide; CRH: cytokine receptor homology domain; Ig: Ig-like doma
CD: cytoplasmic domain.When a cytokine binds to LIFR (primarily through the
fibronectin type III domain), LIFR associates with glyco-
protein 130 (gp130), and the addition of gp130 creates a
high-affinity complex [53]. The dimerization of LIFR
and gp130 causes cytoplasmic JAK to be phosphorylated
at the tyrosine 705 residue. JAK then phosphorylates tyro-
sine residues on the intercellular domains of gp130 and
LIFR [54,55]. In turn, STAT3 proteins are phosphorylated
[54]. STAT3 then forms a homodimer and moves to the
nucleus, where it binds to cytokine-responsive elements
and ultimately activates gene transcription (Figure 3)
[55-57]. Alternatively, LIFR binding can stimulate JAK/
STAT1 in a similar manner [56,57]. To a lesser extent,
the SHP2/RAS/MAPK pathway can also be activated
(Figure 3) [55,58,59]. LIFR is also present in a soluble
form, which binds to LIF in a competitive manner, so
that LIF cannot exert its effects on cells [60]. In some
cell types, after signaling is completed, LIFR is internal-
ized through endocytosis and degraded [61-63].
LIFR ligands linked to neonatal development
Leukemia inhibitory factor receptor ligands: bone
remodeling, neuronal development, and myoblast
differentiation
LIF is a pleiotropic cytokine, secreted by a variety of cell
types, including epithelial and stromal cells of the endo-
metrium [64], osteoblasts [65,66], bone marrow stromal
cells, fibroblasts, astrocytes, heart myoblasts, T lympho-
cytes, monocytes, and thymic epithelial cells among
others [67].
The traits of the Lif knockout mice that are shared
with STWS include giant osteoclasts [68] and some loss
of motor neurons [69]. Giant osteoclasts are the result
of interactions between FRA2 and c-JUN with LIF [68].
On the other hand, some have argued that there is no
severe neuronal dysfunction in Lif-/- mice [70].
LIF and CT-1 play a role in bone resorption. LIF and
CT-1 were found to stimulate the proliferation and differ-
entiation of both osteoblasts and osteoclasts [71-75]. Spe-
cifically, LIF and CT-1 stimulate osteoclast formation by
enhancing the expression of RANKL (receptor activator of
nuclear factor kappa-B ligand). RANKL is the primary
mediator of osteoclast formation, function, and survival.indicate the location of the 19 exons (figure not to scale). The domains
gion of the protein (extracellular, transmembrane, or cytoplasmic).
in; FNIII: type III fibronectin domain; TM: transmembrane domain;
Figure 3 IL-6 family cytokines that signal through the leukemia inhibitory factor receptor (LIFR). After cytokine binding, LIFR associates
with gp130 to initiate the JAK/STAT1 or JAK/STAT3 pathway. In some cases, the SHP2/RAS/MAPK pathway is initiated. Oncostatin-M (OSM) and
leukemia inhibitory factor (LIF) bind to LIFR without any other associated receptors. Cardiotrophin-1 (CT-1) binds to another receptor which
associates with LIFR/gp130. Ciliary neurotrophic factor (CNTF) first binds to its receptor (CNTFR), which then recruits LIFR, followed by gp130.
Cardiotrophin-like cytokine factor-1 (CLCF-1) binds with either cytokine receptor-like factor-1 (CRLF-1) or soluble ciliary neurotrophic factor
receptor (sCNTFR) before binding to CNTFR.
Table 2 Stüve-Wiedemann syndrome (STWS) with the
corresponding molecular etiology
STWS phenotype Cytokine Reference
Smooth tongue LIF, CNTF [7,77]




Paradoxical sweating CLCF1/CRLF1 [9,13,106]
Dysphagia CT-1?, OSM?, CLCF1/
CRLF1?
[20,70,107,108]
Respiratory distress CT-1?, OSM? [82]
Short stature CNTF [58,70,89,100]
Each of the cytokines signal through the leukemia inhibitory factor receptor
(LIFR). In STWS, the LIFR gene is mutated, and due to the mutation, cytokine
signaling is blocked, and the corresponding manifestations of STWS occur.
Only symptoms for which the mechanism has been explored are listed. Those
followed by a question mark are still under considerable speculation. LIF:
leukemia inhibitory factor; CNTF: ciliary neurotrophic factor; OSM: oncostatin-M;
CT-1: cardiotrophin-1; CLCF1: cardiotrophin-like cytokine factor-1; CRLF1: cytokine
receptor-like factor-1.
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density, volume and strength. Ct-1 knockout mice showed
osteopenia at the neonatal stage. Taken together, loss of
LIF and CT-1 signaling in STWS due to the absence of a
functional LIFR most likely contributes to osteopenia and
bone-specific traits seen in STWS.
LIF also acts as a neurotrophic factor [76]. The smooth
tongue phenotype seen in STWS is due to a lack of fun-
giform papillae. Fungiform papillae do not develop in
the absence of LIF and CNTF signaling that cannot be
mediated by the mutated LIFR gene [77]. Furthermore,
LIF and CNTF are known to stimulate cholinergic differ-
entiation in sympathetic neurons, inducing choline acet-
yletransferase gene expression, which in turn promotes the
survival of cholinergic neurons [78]. Similarly, LIF and CT-
1 are important for the cholinergic transdifferentiation of
cardiac sympathetic neurons. Hence, it is likely that a lack
of LIF and CT-1 downstream signaling leads to the cardio-
vascular phenotype seen in STWS [79-81]. LIF also has
neuromodulary roles in the respiratory airways [82]. Table 2
summarizes the relationship between STWS symptoms
and the loss of specific cytokine signaling that cannot be
Mikelonis et al. Orphanet Journal of Rare Diseases 2014, 9:34 Page 6 of 11
http://www.ojrd.com/content/9/1/34mediated by LIFR due to a mutated LIFR gene and absence
of LIFR protein.
LIF induces skeletal muscle satellite cells to proliferate
via the JAK2-STAT3 pathway [83,84]. Satellite cells are
quiescent resident multipotential cells that are essential
for muscle growth and hypertrophy, and are recruited
for muscle growth, regeneration, and repair of injured
muscles. LIF is able to both promote or inhibit myoblast
differentiation, depending upon conditions [83,85], and
acts as a survival factor for myoblasts [86]. Thus, the
lack of LIF downstream signaling resulting from an ab-
sence of LIFR in STWS may be a contributing factor in
the muscular symptoms associated with STWS.
Oncostatin-M (OSM): bone and motor neuron
development
OSM shares similarities with LIF. For example, both are
able to induce the differentiation of myeloid leukemia cells
to macrophage-like cells in mice [87]. LIF and OSM are
located near each other on chromosome 22, and their ar-
rangements suggest that LIF and OSM may be the result
of a gene duplication event of an ancestral gene [88].
OSM, CT-1, and to a lesser extent, LIF, are involved in
bone formation in vitro and in vivo [58,89]. OSM can
bind to either OSMR:gp130 or LIFR:gp130 heterodi-
meric receptors. The effect of OSM on bone formation
depends on which receptor complex it acts through.
When OSM acts through LIFR:gp130 receptor complex ,
it promotes bone formation by inhibiting sclerostin, for
example. Conversely, when OSM acts through OSMR:
gp130 receptor complex, it promotes bone resorption by
stimulating RANKL production and osteoclast formation
[71,90,91]. Therefore, in STWS, the lack of OSM signal-
ing through LIFR:gp130 receptor complex is not able to
contribute positively to bone formation, and, in addition,
OSM signaling mediated by OSMR:gp130 promotes
bone resorption, thus playing a role in osteopenia.
The number of motor neurons in the facial nucleus,
lumbar spinal cord, and nucleus ambiguous are severely
reduced in mice that do not express LIFR. Importantly
for STWS, the nucleus ambiguus innervates the esopha-
gus, pharynx, larynx, and coordinates swallowing. The
nucleus ambiguus is responsible for initiating the re-
spiratory rhythm. LIF and CNTF enhance the differenti-
ation and survival of motor neurons, yet Li et al. found
that mice deficient in CNTF do not show a decrease in
motor neurons, and that mice deficient in LIF do not
show any severe neuronal defects. Therefore, Li et al.
demonstrated that the reduction in motor neurons seen
in STWS is due to the inability of OSM and CT-1 to sig-
nal through the mutated LIFR [70]. Taken together,
OSM and CT-1 are the most likely LIFR ligands respon-
sible for the respiratory distress and dysphagia seen in
STWS. Others have argued that the respiratory distressof STWS may be secondary to myotonia instead of pul-
monary hypoplasia [20].
Cardiotrophin-1 (CT-1): heart, motor neurons, and airway
smooth muscle
CT-1, along with LIF, was shown to play an important role
in the cholinergic transdifferentiation of cardiac sympa-
thetic neurons in rodents [79,92]. Specifically, CT-1 re-
duced the number of preganglionic sympathetic neurons,
which are important for inducing heart rate, ventricular
pressure, and contractility [93]. CT-1 is also known to in-
duce cardiac myocyte hypertrophy and vascular smooth
muscle cell proliferation in vitro [80]. Therefore, the lack
of CT-1 signaling in STWS may play a role in the cardio-
vascular phenotype [94]. CT-1 was also found to play a
role in motor neuron survival [95]. As indicated above,
CT-1 plays essential roles in bone and skeletal develop-
ment. Additionally, a role for CT-1 in airway smooth
muscle cells has been identified [96,97]. Therefore, an ab-
sence of CT-1 signaling in STWS may contribute to the
respiratory phenotype of STWS.
Ciliary Neurotrophic Factor (CNTF): motor neuron survival
and contribution to short stature
CNTF was first isolated from chick eyes, where it helped
the survival of embryonic ciliary ganglia [98]. CNTF is
expressed in the developing nervous system, particularly
in the motor neurons, and it plays a role in motor
neuron survival [70].
STWS includes low birth weight and length, delayed
growth, and short stature [13,20]. While one symptom
of STWS may be dwarfism, since LIFR-/- mice exhibit
dwarfism [89,99], the short stature within the trunk re-
gion seen in STWS may, in part, be secondary to pro-
gressive scoliosis, however this would not explain the
reduction in leg length [13]. Relevant to both explana-
tions, CNTF is expressed in chondrocytes, the cells that
are responsible for longitudinal bone growth at the
growth plate [89,100]. LIF and CT-1 are also expressed
in chondrocytes [101,102], however LIF and CT-1 do
not induce chondrogenesis [89]. A short bone phenotype
is seen in Cntf knockout mice [100]. Therefore, impair-
ment of CNTF signaling in the absence of a functional
LIFR in STWS is the most likely cause of the short stat-
ure phenotype observed in STWS.
Cardiotrophin-like Cytokine Factor-1 (CLCF-1): autonomic
functioning
Crisponi syndrome and cold-induced sweating syndrome
share some features with STWS, such as feeding difficul-
ties, trismus, paradoxical sweating (i.e., sweating with
low body temperatures; [9,20]), and hyperthermic epi-
sodes [10]. Crisponi syndrome is now considered to be
the same disorder as cold-induced sweating syndrome
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mutations in the CLCF-1 or CRLF-1 genes [9]. CLCF-1
binds with either CRLF-1 (cytokine receptor-like factor-1)
or sCNTFR (soluble ciliary neurotrophic factor receptor)
and then competes with CNTF (ciliary neurotrophic fac-
tor) for the receptor complex composed of CNTFR, LIFR
and gp130 (Figure 3; [51,104,105]). Therefore, it seems that
the dysautomonic symptoms seen in STWS are caused by
a lack of CLCF-1/CRLF-1 signaling due to a mutated LIFR
gene [13,21]. Adding to this evidence, in mice, Clcf-1/Crlf-
1 appears to be responsible for cholinergic differentiation
of neurons innervating sweat glands [106].
Mice lacking Crlf-1, Cntfr and Clcf-1 are unable to
suckle and die shortly after birth [107]. These mice also
have a reduced number of motor neurons in the facial
nucleus [108]. Therefore, a lack of CLCF-1/CRLF-1 sig-
naling is the best candidate for the dysphagia and facial
muscle contractions seen in STWS.
A note about bowing of the long bones
Myotonia and mechanical forces May play a role
The etiology for each of the major STWS symptoms dis-
cussed thus far has been on a cellular level. However
mechanical forces also may play an important role in
STWS. Congenital bowing of the long bones is a hall-
mark feature of STWS [1], but it is not unique to STWS
and manifests in other syndromes including type IX
Ehlers-Danlos syndrome, Campomelic Displasia, Larsen
syndrome and other conditions. [109-112]. Some have
suggested that prenatal bowing of the long bones results
from the mechanical forces of imbalanced muscles act-
ing on structurally weak bones in utero [113-115].
Begam et al. found that prior to birth, patients with
STWS have myotonia [20], which could produce imbal-
anced muscular force. Other studies also noted myo-
tonia as a symptom [16,116,117]. Therefore, bowing of
the long bones in STWS may be due to mechanical
forces acting on bones that are weakened by inadequate
signaling.
Managing Stüve-Wiedemann syndrome
There are no treatments available for STWS at this time.
However, aminoglycosides are capable of inducing the
read-through of premature stop codons. Since prema-
ture stop codons are present in many LIFR mutations
associated with STWS, the aminoglycoside gentamycin
was tested on fibroblast cultures from STWS patients.
High doses of gentamycin restored lost JAK/STAT
signaling. Although high doses of gentamycin are nephro-
and ototoxic in vivo, perhaps a similar treatment modality
should be explored further [55].
Currently, STWS is managed symptomatically, with pre-
vention of lung aspirations being a top priority [12]. Since
STWS patients are unable to maintain a respiratoryrhythm or swallow during the first year of life, oftentimes,
intubation, nasogastric tube feeding and/or gastrostomy
are necessary [118]. Although swallowing abilities gener-
ally improve over time [13], it is recommended that care-
takers are vigilant while the patient is eating for at least
the first five years of life as aspiration and choking can still
occur later in childhood [18]. Furthermore, children with
STWS have been noted to bite their tongue and cause
damage. This can be prevented by using an appliance to
cover the teeth to prevent tongue damage until the child
gains enough self-awareness to limit unintentional tongue
biting [118].
Osteopenia or osteoporosis in STWS may be treated
using bisphosphonates with calcium, 1,25 OH vitamin D
and/or human growth hormone [18]. Surgery is often ne-
cessary to improve other bone malformations [13,119],
and physical therapy may also be helpful [118].
In STWS, it is important to protect the eyes from dam-
age, including sunlight, to prevent visual loss. Once ocular
issues arise (e.g., corneal opacities, hypolacrimation and
impaired pupillary function), a balanced approach is rec-
ommended [120]. The results of corneal transplantation
in children with anesthetic corneas are poor [121]. How-
ever, corneal opacities can be corrected with keratectomy
procedures [17]. For hypolacrimation, the frequent use of
artificial tear drops and ointment at night are recom-
mended. Additionally, lacrimal punctum dilation and
punctual plugs can be implemented to encourage the ac-
cumulation of a tear reservoir. Tarsorrhaphies can be per-
formed to help protect the cornea from exposure.
Tropicamide eye drops are used to help dilate the pupil. If
tropicamide fails, iridectomies are recommended [120].
Prior to surgery, physicians and STWS patients and
families should be advised of certain complications which
may occur with STWS. Specifically, some have argued that
anesthesia increases the risk of malignant hyperthermia in
STWS [122,123]. However, others have recently argued
against this claim [17]. Additionally, tetraplegia was report
in two STWS patients within 40 hours of an otherwise un-
eventful thoracolumbar scoliosis corrective surgery.
Pizones et al. therefore recommended close monitoring
after spinal surgery regardless of the course of the surgery.
The first symptom of delayed tetraplegia in these cases
was acute severe neck pain [4].
Future directions
More information about etiology
Although most reported cases of STWS are associated
with a mutation in the LIFR gene [7], there are some di-
agnosed cases of STWS in which the patient does not
have a LIFR mutation [13]. These cases should be ex-
plored further. It is possible that those patients were
misdiagnosed, as STWS shares many traits with other
syndromes [10,20,99]. However, it is also very likely that
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shift mutations in the LIFR gene in different individuals
have also been reported to show differing outcomes or
severity [7].
Even in the cases where LIFR signaling is known to be
the root cause of STWS, connections between signaling
and symptoms have not been fully elucidated. It is
known that many cytokines have redundant roles. It is
likely to expect that the cytokines interact with one an-
other, and that other proteins involved in STWS indir-
ectly will be discovered with additional research.
Improving outcomes
It has been noted that STWS patients who survive the first
year of life show an improvement in their ability to swallow
and regulate breathing [13]. This is a crucial improvement,
as feeding difficulties, respiratory failure and hyperthermic
episodes are the most frequently cited causes of early death
in STWS [6,7,10]. However, it appears that the reason be-
hind this improvement has not yet been explored on a
physiological level, or on a molecular level. It would be inter-
esting to learn what causes this shift in STWS phenotypes
over time, and what causes these serious symptoms to occa-
sionally return to cause unexpected death. Furthermore, this
knowledge could have important implications in the devel-
opment of treatments which are currently unavailable.
Conclusions
STWS is a rare bent-bone dysplasia with dysautonomic
manifestations that is generally caused by the autosomal re-
cessive inheritance of a mutated LIFR gene. The symptoms
of STWS are the result of a lack of LIFR signaling, although
the exact mechanisms remain unclear for most phenomena.
There is currently no treatment available for STWS. Instead,
symptoms are managed accordingly. Although STWS is a
rare condition, the prognosis remains poor and there are
many unanswered questions regarding its pathology. There-
fore, further research is needed to provide a better mechan-
istic understanding as well as to make progress toward novel
therapies that take advantage of what we do know about the
targeted manipulation of specific signaling pathways.
Consent
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tient, who is now if legal age, for the publication of this
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